Research Article
Tumor Characteristics Associated with Lymph Node Metastasis and Prognosis in Patients with ERBB2-Positive Gastric Cancer
Table 1
Patients’ characteristics.
| | Variable | N (%) |
| | Gender | | Male | 98 (80.3%) | | Female | 24 (19.7%) |
| | Age (years) | | ≤60 | 20 (16.4%) | | >60 | 102 (83.6%) |
| | Tumor size | | ≤4 cm | 64 (52.5%) | | >4 cm | 58 (47.5%) |
| | AJCC T stage | | PT1 | 15 (12.3%) | | PT2 | 9 (7.4%) | | PT3 | 57 (46.7%) | | PT4a/PT4b | 41 (33.6%) |
| | AJCC N stage | | PN0 | 40 (32.8%) | | PN1 | 28 (23.0%) | | PN2 | 17 (13.9%) | | PN3 | 37 (30.3%) |
| | AJCC stage | | I | 17 (13.9%) | | II | 48 (39.3%) | | III | 55 (45.1%) | | IV | 2 (1.6%) |
| | Histologic classification | | Moderately differentiated | 58 (47.5%) | | Moderately poorly differentiated | 54 (44.3%) | | Poorly differentiated | 10 (8.2%) |
| | Histology | | Conventional AD | 101 (82.8%) | | Mucinous AD | 10 (8.2%) | | Papillary AD | 4 (3.3%) | | Signet-ring cell carcinoma | 6 (4.9%) | | Adenosquamous carcinoma | 1 (0.8%) |
| | Tumor location | | Upper 1/3 | 41 (33.6%) | | Middle 1/3 | 10 (8.2%) | | Lower 1/3 | 58 (47.5%) | | Mix | 13 (10.7%) |
| | Vascular invasion | | (−) | 59 (48.4%) | | (+) | 63 (51.6%) |
| | Neural invasion | | (−) | 62 (50.8%) | | (+) | 60 (49.2%) |
| | Type of gastrectomy | | Proximal subtotal gastrectomy | 20 (16.4%) | | Distal gastrectomy | 58 (47.5%) | | Total gastrectomy | 44 (36.1%) |
| | Postoperative chemotherapy | | Yes | 105 (86.1%) | | No | 17 (13.9%) |
| | Chemotherapy approach | | S-1 | 36 (29.5%) | | CapeOX/SOX | 69 (56.6%) |
| | Lauren type | | I (intestinal type) | 108 (88.5%) | | D (diffuse type) | 7 (5.7%) | | M (mixed type) | 7 (5.7%) |
| | Tumor deposit | | Yes | 21 (17.2%) | | No | 101 (82.3%) |
|
|
Abbreviations: CapeOX-capecitabine and oxaliplatin, SOX-S-1 plus oxaliplatin, AD-adenocarcinoma.
|
